Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand
Punnee Pitisuttithum*, Supachai Rerks-Ngarm, Valai Bussaratid, Jittima Dhitavat, Wirach Maekanantawat, Swangjai Pungpak, Pravan Suntharasamai, Sirivan Vanijanonta, Sorachai Nitayapan, Jaranit Kaewkungwal, Michael Benenson, Patricia Morgan, Robert J. O'Connell, Jeffrey Berenberg, Sanjay Gurunathan, Donald P. Francis, Robert Paris, Joseph Chiu, Donald Stablein, Nelson L. MichaelJean Louis Excler, Merlin L. Robb, Jerome H. Kim
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
45Scopus
citations
Fingerprint
Dive into the research topics of 'Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand'. Together they form a unique fingerprint.